Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen

Twenty-seven subjects with squamous cell cancer of the head and neck received the neoadjuvant IRX-2 immunotherapy regimen prior to surgery in a Phase 2 trial. Pretreatment tumor biopsies were compared with the primary tumor surgical specimens for lymphocyte infiltration, necrosis and fibrosis, using...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Immunology, Immunotherapy Immunotherapy, 2012-06, Vol.61 (6), p.771-782
Main Authors: Berinstein, Neil L., Wolf, Gregory T., Naylor, Paul H., Baltzer, Lorraine, Egan, James E., Brandwein, Harvey J., Whiteside, Theresa L., Goldstein, Lynn C., El-Naggar, Adel, Badoual, Cecile, Fridman, Wolf-Herve, White, J. Michael, Hadden, John W.
Format: Article
Language:English
Subjects:
Adult
Aged
Antigens
Antineoplastic agents
Biological and medical sciences
Biopsy
Cancer
Cancer Research
CD3 antigen
CD4 antigen
CD8 antigen
Clinical trials
Cytokines
Cytokines - administration & dosage
Cytokines - immunology
Female
Fibrosis
Head & neck cancer
Head and neck cancer
Head and Neck Neoplasms - immunology
Head and Neck Neoplasms - pathology
Head and Neck Neoplasms - therapy
Human papillomavirus
Humans
Immunohistochemistry
Immunology
Immunotherapy
Laboratories
Lymphocytes
Lymphocytes B
Lymphocytes T
Lymphocytes, Tumor-Infiltrating - immunology
Macrophages
Male
Medical sciences
Medicine
Medicine & Public Health
Metastases
Middle Aged
Necrosis
Oncology
Original Article
Otorhinolaryngology (head neck, general aspects and miscellaneous)
Otorhinolaryngology. Stomatology
Pharmacology. Drug treatments
Regression Analysis
Squamous cells
Stains
Stroma
Surgery
Survival Analysis
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c533t-876124431591184118138d1a033bdb4a5cee1fe843b04624c5d45f5a369cb7ba3
cites cdi_FETCH-LOGICAL-c533t-876124431591184118138d1a033bdb4a5cee1fe843b04624c5d45f5a369cb7ba3
container_end_page 782
container_issue 6
container_start_page 771
container_title Cancer Immunology, Immunotherapy
container_volume 61
creator Berinstein, Neil L.
Wolf, Gregory T.
Naylor, Paul H.
Baltzer, Lorraine
Egan, James E.
Brandwein, Harvey J.
Whiteside, Theresa L.
Goldstein, Lynn C.
El-Naggar, Adel
Badoual, Cecile
Fridman, Wolf-Herve
White, J. Michael
Hadden, John W.
description Twenty-seven subjects with squamous cell cancer of the head and neck received the neoadjuvant IRX-2 immunotherapy regimen prior to surgery in a Phase 2 trial. Pretreatment tumor biopsies were compared with the primary tumor surgical specimens for lymphocyte infiltration, necrosis and fibrosis, using hematoxylin and eosin stain and immunohistochemistry in 25 subjects. Sections were examined by three pathologists. Relative to pretreatment biopsies, increases in lymphocyte infiltration (LI) were seen using H and E or immunohistochemistry. CD3+ CD4+ T cells and CD20+ B cells were primarily found in the peritumoral stroma and CD3+ CD8+ T cells and CD68+ macrophages were mainly intratumoral. LI in the surgical specimens were associated with reductions in the primary tumor size. Improved survival at 5 years was correlated with high overall LI in the tumor specimens. Neoadjuvant IRX-2 immunotherapy regimen may restore immune responsiveness presumably by mobilizing tumor infiltrating effector lymphocytes and macrophages into the tumor.
doi_str_mv 10.1007/s00262-011-1134-z
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5300054</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1020843870</sourcerecordid><originalsourceid>FETCH-LOGICAL-c533t-876124431591184118138d1a033bdb4a5cee1fe843b04624c5d45f5a369cb7ba3</originalsourceid><addsrcrecordid>eNqNkd-L1DAQx4so3nr6B_giARF8qU5-temLIMepCweCKPgW0nS6zdmma5Iqe3_9ZW_X8xQEH0IyyWe-M5NvUTyl8IoC1K8jAKtYCZSWlHJRXt0rVlTwfKMkvV-sgAsoawBxUjyK8TIfGDTNw-KEMZB1VatVkdbeBjQROzLupu0w211C4nzvxhRMcrPPAdnmE_oUyU-XBjKg6YjxHfFovxFrvMVAUlZJWeWGSAOS9aevJSNumhY_5ziY7Y4E3LgJ_ePiQW_GiE-O-2nx5d3557MP5cXH9-uztxellZynUtUVZUJwKhtKlciLctVRA5y3XSuMtIi0RyV4C6JiwspOyF4aXjW2rVvDT4s3B93t0k7Y2TxCMKPeBjeZsNOzcfrPF-8GvZl_aMkBQIos8PIoEObvC8akJxctjqPxOC9RU2CQy6sa_gOldaNAVXVGn_-FXs5L8PknbqgKFG1YpuiBsmGOMWB_2zcFvbdfH-zX2X69t19f5Zxndwe-zfjldwZeHAETrRn7kM1z8Tcnm6oRsOfYgYv5yW8w3G3xX9WvAfFzyHc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1017608192</pqid></control><display><type>article</type><title>Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen</title><source>Springer Nature</source><source>PubMed Central</source><creator>Berinstein, Neil L. ; Wolf, Gregory T. ; Naylor, Paul H. ; Baltzer, Lorraine ; Egan, James E. ; Brandwein, Harvey J. ; Whiteside, Theresa L. ; Goldstein, Lynn C. ; El-Naggar, Adel ; Badoual, Cecile ; Fridman, Wolf-Herve ; White, J. Michael ; Hadden, John W.</creator><creatorcontrib>Berinstein, Neil L. ; Wolf, Gregory T. ; Naylor, Paul H. ; Baltzer, Lorraine ; Egan, James E. ; Brandwein, Harvey J. ; Whiteside, Theresa L. ; Goldstein, Lynn C. ; El-Naggar, Adel ; Badoual, Cecile ; Fridman, Wolf-Herve ; White, J. Michael ; Hadden, John W.</creatorcontrib><description>Twenty-seven subjects with squamous cell cancer of the head and neck received the neoadjuvant IRX-2 immunotherapy regimen prior to surgery in a Phase 2 trial. Pretreatment tumor biopsies were compared with the primary tumor surgical specimens for lymphocyte infiltration, necrosis and fibrosis, using hematoxylin and eosin stain and immunohistochemistry in 25 subjects. Sections were examined by three pathologists. Relative to pretreatment biopsies, increases in lymphocyte infiltration (LI) were seen using H and E or immunohistochemistry. CD3+ CD4+ T cells and CD20+ B cells were primarily found in the peritumoral stroma and CD3+ CD8+ T cells and CD68+ macrophages were mainly intratumoral. LI in the surgical specimens were associated with reductions in the primary tumor size. Improved survival at 5 years was correlated with high overall LI in the tumor specimens. Neoadjuvant IRX-2 immunotherapy regimen may restore immune responsiveness presumably by mobilizing tumor infiltrating effector lymphocytes and macrophages into the tumor.</description><identifier>ISSN: 0340-7004</identifier><identifier>EISSN: 1432-0851</identifier><identifier>DOI: 10.1007/s00262-011-1134-z</identifier><identifier>PMID: 22057678</identifier><identifier>CODEN: CIIMDN</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Adult ; Aged ; Antigens ; Antineoplastic agents ; Biological and medical sciences ; Biopsy ; Cancer ; Cancer Research ; CD3 antigen ; CD4 antigen ; CD8 antigen ; Clinical trials ; Cytokines ; Cytokines - administration &amp; dosage ; Cytokines - immunology ; Female ; Fibrosis ; Head &amp; neck cancer ; Head and neck cancer ; Head and Neck Neoplasms - immunology ; Head and Neck Neoplasms - pathology ; Head and Neck Neoplasms - therapy ; Human papillomavirus ; Humans ; Immunohistochemistry ; Immunology ; Immunotherapy ; Laboratories ; Lymphocytes ; Lymphocytes B ; Lymphocytes T ; Lymphocytes, Tumor-Infiltrating - immunology ; Macrophages ; Male ; Medical sciences ; Medicine ; Medicine &amp; Public Health ; Metastases ; Middle Aged ; Necrosis ; Oncology ; Original Article ; Otorhinolaryngology (head neck, general aspects and miscellaneous) ; Otorhinolaryngology. Stomatology ; Pharmacology. Drug treatments ; Regression Analysis ; Squamous cells ; Stains ; Stroma ; Surgery ; Survival Analysis ; Tumors</subject><ispartof>Cancer Immunology, Immunotherapy, 2012-06, Vol.61 (6), p.771-782</ispartof><rights>Springer-Verlag 2011</rights><rights>2015 INIST-CNRS</rights><rights>Springer-Verlag 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c533t-876124431591184118138d1a033bdb4a5cee1fe843b04624c5d45f5a369cb7ba3</citedby><cites>FETCH-LOGICAL-c533t-876124431591184118138d1a033bdb4a5cee1fe843b04624c5d45f5a369cb7ba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300054/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300054/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=25969408$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22057678$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Berinstein, Neil L.</creatorcontrib><creatorcontrib>Wolf, Gregory T.</creatorcontrib><creatorcontrib>Naylor, Paul H.</creatorcontrib><creatorcontrib>Baltzer, Lorraine</creatorcontrib><creatorcontrib>Egan, James E.</creatorcontrib><creatorcontrib>Brandwein, Harvey J.</creatorcontrib><creatorcontrib>Whiteside, Theresa L.</creatorcontrib><creatorcontrib>Goldstein, Lynn C.</creatorcontrib><creatorcontrib>El-Naggar, Adel</creatorcontrib><creatorcontrib>Badoual, Cecile</creatorcontrib><creatorcontrib>Fridman, Wolf-Herve</creatorcontrib><creatorcontrib>White, J. Michael</creatorcontrib><creatorcontrib>Hadden, John W.</creatorcontrib><title>Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen</title><title>Cancer Immunology, Immunotherapy</title><addtitle>Cancer Immunol Immunother</addtitle><addtitle>Cancer Immunol Immunother</addtitle><description>Twenty-seven subjects with squamous cell cancer of the head and neck received the neoadjuvant IRX-2 immunotherapy regimen prior to surgery in a Phase 2 trial. Pretreatment tumor biopsies were compared with the primary tumor surgical specimens for lymphocyte infiltration, necrosis and fibrosis, using hematoxylin and eosin stain and immunohistochemistry in 25 subjects. Sections were examined by three pathologists. Relative to pretreatment biopsies, increases in lymphocyte infiltration (LI) were seen using H and E or immunohistochemistry. CD3+ CD4+ T cells and CD20+ B cells were primarily found in the peritumoral stroma and CD3+ CD8+ T cells and CD68+ macrophages were mainly intratumoral. LI in the surgical specimens were associated with reductions in the primary tumor size. Improved survival at 5 years was correlated with high overall LI in the tumor specimens. Neoadjuvant IRX-2 immunotherapy regimen may restore immune responsiveness presumably by mobilizing tumor infiltrating effector lymphocytes and macrophages into the tumor.</description><subject>Adult</subject><subject>Aged</subject><subject>Antigens</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Biopsy</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>CD3 antigen</subject><subject>CD4 antigen</subject><subject>CD8 antigen</subject><subject>Clinical trials</subject><subject>Cytokines</subject><subject>Cytokines - administration &amp; dosage</subject><subject>Cytokines - immunology</subject><subject>Female</subject><subject>Fibrosis</subject><subject>Head &amp; neck cancer</subject><subject>Head and neck cancer</subject><subject>Head and Neck Neoplasms - immunology</subject><subject>Head and Neck Neoplasms - pathology</subject><subject>Head and Neck Neoplasms - therapy</subject><subject>Human papillomavirus</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Immunology</subject><subject>Immunotherapy</subject><subject>Laboratories</subject><subject>Lymphocytes</subject><subject>Lymphocytes B</subject><subject>Lymphocytes T</subject><subject>Lymphocytes, Tumor-Infiltrating - immunology</subject><subject>Macrophages</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Metastases</subject><subject>Middle Aged</subject><subject>Necrosis</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Otorhinolaryngology (head neck, general aspects and miscellaneous)</subject><subject>Otorhinolaryngology. Stomatology</subject><subject>Pharmacology. Drug treatments</subject><subject>Regression Analysis</subject><subject>Squamous cells</subject><subject>Stains</subject><subject>Stroma</subject><subject>Surgery</subject><subject>Survival Analysis</subject><subject>Tumors</subject><issn>0340-7004</issn><issn>1432-0851</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNqNkd-L1DAQx4so3nr6B_giARF8qU5-temLIMepCweCKPgW0nS6zdmma5Iqe3_9ZW_X8xQEH0IyyWe-M5NvUTyl8IoC1K8jAKtYCZSWlHJRXt0rVlTwfKMkvV-sgAsoawBxUjyK8TIfGDTNw-KEMZB1VatVkdbeBjQROzLupu0w211C4nzvxhRMcrPPAdnmE_oUyU-XBjKg6YjxHfFovxFrvMVAUlZJWeWGSAOS9aevJSNumhY_5ziY7Y4E3LgJ_ePiQW_GiE-O-2nx5d3557MP5cXH9-uztxellZynUtUVZUJwKhtKlciLctVRA5y3XSuMtIi0RyV4C6JiwspOyF4aXjW2rVvDT4s3B93t0k7Y2TxCMKPeBjeZsNOzcfrPF-8GvZl_aMkBQIos8PIoEObvC8akJxctjqPxOC9RU2CQy6sa_gOldaNAVXVGn_-FXs5L8PknbqgKFG1YpuiBsmGOMWB_2zcFvbdfH-zX2X69t19f5Zxndwe-zfjldwZeHAETrRn7kM1z8Tcnm6oRsOfYgYv5yW8w3G3xX9WvAfFzyHc</recordid><startdate>20120601</startdate><enddate>20120601</enddate><creator>Berinstein, Neil L.</creator><creator>Wolf, Gregory T.</creator><creator>Naylor, Paul H.</creator><creator>Baltzer, Lorraine</creator><creator>Egan, James E.</creator><creator>Brandwein, Harvey J.</creator><creator>Whiteside, Theresa L.</creator><creator>Goldstein, Lynn C.</creator><creator>El-Naggar, Adel</creator><creator>Badoual, Cecile</creator><creator>Fridman, Wolf-Herve</creator><creator>White, J. Michael</creator><creator>Hadden, John W.</creator><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20120601</creationdate><title>Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen</title><author>Berinstein, Neil L. ; Wolf, Gregory T. ; Naylor, Paul H. ; Baltzer, Lorraine ; Egan, James E. ; Brandwein, Harvey J. ; Whiteside, Theresa L. ; Goldstein, Lynn C. ; El-Naggar, Adel ; Badoual, Cecile ; Fridman, Wolf-Herve ; White, J. Michael ; Hadden, John W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c533t-876124431591184118138d1a033bdb4a5cee1fe843b04624c5d45f5a369cb7ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antigens</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Biopsy</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>CD3 antigen</topic><topic>CD4 antigen</topic><topic>CD8 antigen</topic><topic>Clinical trials</topic><topic>Cytokines</topic><topic>Cytokines - administration &amp; dosage</topic><topic>Cytokines - immunology</topic><topic>Female</topic><topic>Fibrosis</topic><topic>Head &amp; neck cancer</topic><topic>Head and neck cancer</topic><topic>Head and Neck Neoplasms - immunology</topic><topic>Head and Neck Neoplasms - pathology</topic><topic>Head and Neck Neoplasms - therapy</topic><topic>Human papillomavirus</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Immunology</topic><topic>Immunotherapy</topic><topic>Laboratories</topic><topic>Lymphocytes</topic><topic>Lymphocytes B</topic><topic>Lymphocytes T</topic><topic>Lymphocytes, Tumor-Infiltrating - immunology</topic><topic>Macrophages</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Metastases</topic><topic>Middle Aged</topic><topic>Necrosis</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Otorhinolaryngology (head neck, general aspects and miscellaneous)</topic><topic>Otorhinolaryngology. Stomatology</topic><topic>Pharmacology. Drug treatments</topic><topic>Regression Analysis</topic><topic>Squamous cells</topic><topic>Stains</topic><topic>Stroma</topic><topic>Surgery</topic><topic>Survival Analysis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Berinstein, Neil L.</creatorcontrib><creatorcontrib>Wolf, Gregory T.</creatorcontrib><creatorcontrib>Naylor, Paul H.</creatorcontrib><creatorcontrib>Baltzer, Lorraine</creatorcontrib><creatorcontrib>Egan, James E.</creatorcontrib><creatorcontrib>Brandwein, Harvey J.</creatorcontrib><creatorcontrib>Whiteside, Theresa L.</creatorcontrib><creatorcontrib>Goldstein, Lynn C.</creatorcontrib><creatorcontrib>El-Naggar, Adel</creatorcontrib><creatorcontrib>Badoual, Cecile</creatorcontrib><creatorcontrib>Fridman, Wolf-Herve</creatorcontrib><creatorcontrib>White, J. Michael</creatorcontrib><creatorcontrib>Hadden, John W.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>ProQuest - Health &amp; Medical Complete保健、医学与药学数据库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health &amp; Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health &amp; Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied &amp; Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer Immunology, Immunotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Berinstein, Neil L.</au><au>Wolf, Gregory T.</au><au>Naylor, Paul H.</au><au>Baltzer, Lorraine</au><au>Egan, James E.</au><au>Brandwein, Harvey J.</au><au>Whiteside, Theresa L.</au><au>Goldstein, Lynn C.</au><au>El-Naggar, Adel</au><au>Badoual, Cecile</au><au>Fridman, Wolf-Herve</au><au>White, J. Michael</au><au>Hadden, John W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen</atitle><jtitle>Cancer Immunology, Immunotherapy</jtitle><stitle>Cancer Immunol Immunother</stitle><addtitle>Cancer Immunol Immunother</addtitle><date>2012-06-01</date><risdate>2012</risdate><volume>61</volume><issue>6</issue><spage>771</spage><epage>782</epage><pages>771-782</pages><issn>0340-7004</issn><eissn>1432-0851</eissn><coden>CIIMDN</coden><abstract>Twenty-seven subjects with squamous cell cancer of the head and neck received the neoadjuvant IRX-2 immunotherapy regimen prior to surgery in a Phase 2 trial. Pretreatment tumor biopsies were compared with the primary tumor surgical specimens for lymphocyte infiltration, necrosis and fibrosis, using hematoxylin and eosin stain and immunohistochemistry in 25 subjects. Sections were examined by three pathologists. Relative to pretreatment biopsies, increases in lymphocyte infiltration (LI) were seen using H and E or immunohistochemistry. CD3+ CD4+ T cells and CD20+ B cells were primarily found in the peritumoral stroma and CD3+ CD8+ T cells and CD68+ macrophages were mainly intratumoral. LI in the surgical specimens were associated with reductions in the primary tumor size. Improved survival at 5 years was correlated with high overall LI in the tumor specimens. Neoadjuvant IRX-2 immunotherapy regimen may restore immune responsiveness presumably by mobilizing tumor infiltrating effector lymphocytes and macrophages into the tumor.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>22057678</pmid><doi>10.1007/s00262-011-1134-z</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0340-7004
ispartof Cancer Immunology, Immunotherapy, 2012-06, Vol.61 (6), p.771-782
issn 0340-7004
1432-0851
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5300054
source Springer Nature; PubMed Central
subjects Adult
Aged
Antigens
Antineoplastic agents
Biological and medical sciences
Biopsy
Cancer
Cancer Research
CD3 antigen
CD4 antigen
CD8 antigen
Clinical trials
Cytokines
Cytokines - administration & dosage
Cytokines - immunology
Female
Fibrosis
Head & neck cancer
Head and neck cancer
Head and Neck Neoplasms - immunology
Head and Neck Neoplasms - pathology
Head and Neck Neoplasms - therapy
Human papillomavirus
Humans
Immunohistochemistry
Immunology
Immunotherapy
Laboratories
Lymphocytes
Lymphocytes B
Lymphocytes T
Lymphocytes, Tumor-Infiltrating - immunology
Macrophages
Male
Medical sciences
Medicine
Medicine & Public Health
Metastases
Middle Aged
Necrosis
Oncology
Original Article
Otorhinolaryngology (head neck, general aspects and miscellaneous)
Otorhinolaryngology. Stomatology
Pharmacology. Drug treatments
Regression Analysis
Squamous cells
Stains
Stroma
Surgery
Survival Analysis
Tumors
title Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-22T12%3A12%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Increased%20lymphocyte%20infiltration%20in%20patients%20with%20head%20and%20neck%20cancer%20treated%20with%20the%20IRX-2%20immunotherapy%20regimen&rft.jtitle=Cancer%20Immunology,%20Immunotherapy&rft.au=Berinstein,%20Neil%20L.&rft.date=2012-06-01&rft.volume=61&rft.issue=6&rft.spage=771&rft.epage=782&rft.pages=771-782&rft.issn=0340-7004&rft.eissn=1432-0851&rft.coden=CIIMDN&rft_id=info:doi/10.1007/s00262-011-1134-z&rft_dat=%3Cproquest_pubme%3E1020843870%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c533t-876124431591184118138d1a033bdb4a5cee1fe843b04624c5d45f5a369cb7ba3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1017608192&rft_id=info:pmid/22057678&rfr_iscdi=true